The recent quarterly was really good and worth a comparison to...

The recent quarterly was really good and worth a comparison to last year's equivalent quarterly. Revenue is certainly exploding just with EPP and the market is barely tapped at this stage. No other Biotechs pumping out this sort of cashflow to fund an exceptional pipeline that I know of.

Q1 1st Quarter FY2023
Cash Receipts: $25,512,000 (up 43.4% yoy)
Expenditures: $8,270,000
Net op. Cash flow: $17,338,000 (up 50% yoy)
Cash: $137.7 MILLION (cash pile growing rapidly)

Q1 1st Quarter FY2022
Cash Receipts: $17,785,000
Expenditures: $6,297,000
Net op. Cash flow: $11,560,000
Cash: $93.4 MILLION (one year ago)

Also saw a good article on *, gives a bit of flesh to the pipeline which was updated in the 4C and Activity Report that Clinuvel released on the 31/10. 3 DNA REPAIR studies with results due in 2022 gives a lot to look forward to in short term and also hopefully news on paediatric access to Scenesse for 12-17 year olds this year.

https://**promotion blocked**/experts/dr-borehams-crucible-the-five-year-plan-is-complete-is-clinuvel-finally-ready-for-its-time-in-the-sun/

All IMO DYOR